Situation
A multinational pharmaceutical company with an oncology portfolio wanted to understand whether, and how, to bring its products to market across the Gulf Cooperation Council (GCC). The company knew that a traditional commercial route wouldn’t work due to affordability and reimbursement barriers to the products. They needed a clear picture of market feasibility and a realistic access strategy — not just a framework, but something they could implement. The end goal was reimbursement, but the company was interested in a bridging program that could build real-world evidence for eventual reimbursement submissions.
Solution
Axios conducted primary market research across the UAE and Kuwait to assess the feasibility of developing a patient access program for each oncology product and market.
- Axios estimated the potential patient pool for each indication and conducted interviews with healthcare professionals to understand treatment pathways, patient needs, and barriers to access.
- Axios assessed the payer and reimbursement landscape and used its affordability modeling to understand patients’ ability to pay.
These insights were brought together into a business case that gave the company a complete view of the opportunity, including the potential patient population, market dynamics, costs, constraints, and feasibility of different access approaches.
Axios then translated these findings into a practical access strategy designed around the realities of each market.
Results
Axios provided a strategy that could move from market insight to implementation, creating a potential pathway to address immediate patient access needs while supporting the company’s longer-term reimbursement objectives. The company was left with a clear understanding of the market opportunity and the feasibility of a patient access program across the UAE and Kuwait and was able to move forward with the program for one of the products.
